Abstract Our knowledge of the pharmacology of the drugs used in pediatric anesthesia has advanced with a greater understanding of their pharmacokinetics (PK) and pharmacodynamics. This has resulted in a refinement of their uses, broader indications, and alternative methods of delivery. For example, methadone is becoming increasingly popular for spinal surgery, the dosing of etomidate has been clarified and the PK of intravenous acetaminophen from neonates to adults has been revealed. Morphine PK have also been clarified, although pharmacodynamic ethnic differences remain unexplained. The optimal size descriptor to predict correct drug doses in the obese remains controversial. Efforts to reduce adverse effects of individual drugs have spawned investigations into beneficial drug interactions, although combinations such as propofol and ketamine await PK and safety review. The nasal route may be a reasonable alternative to intravenous administration for many drugs. Oral ketamine may serve as a valuable premedication for children suffering burns. Expanded indications can have unfavorable consequences; propofol may cause profound hypotension in neonates.
Introduction
Aspects of pharmacology and how these relate to clinical practice remain major areas targeted for future investigation in pediatric anesthesia [1] . The prohibitive cost of developing and bringing new drugs to the market has been partially offset by further exploration of older familiar drugs; refining their use, indications, method of delivery, and interactions with other drugs.
The holy grail of clinical pharmacology is predicting the pharmacokinetics (PK) and pharmacodynamics (PD) of drugs in the individual patient [2] . This requires knowledge of the covariate effects that contribute to variability. Pharmacology is not simply an application of PK, and determinants of drug dose also require an understanding of the variability associated with pharmacodynamic response and a balancing of beneficial effects against unwanted effects [3] . Identification of pharmacodynamic covariates can only benefit children under our care.
New Insights into Old Drugs
Pediatric anesthesiologists have embraced the population approach for determining drug PK and PD [4] . This approach, achieved through nonlinear mixed effects models, provides a means to study variability in drug responses among individuals representative of those in whom the drug will be used clinically. Allometric scaling using an exponent of 0.75 has proved useful to compare the clearance in adults with those in children older than 2 years [5] . The supplemental use of a maturation model (e.g., a sigmoid maturation function based on postmenstrual age) to describe developmental aspects of clearance in children younger than 2 years allows improved dosing estimates [6] .
Morphine
Morphine is widely used throughout the human life span, and numerous pharmacokinetic models have attempted to predict the changes in morphine clearance with weight and age. These models have been evaluated using a large external data set to evaluate their ability to predict morphine dose in preterm and full-term neonates, infants, children, and adults. An allometric model using weight combined with a sigmoid maturation model using postmenstrual age successfully predicted the morphine dose rate within 25 % of target in all age groups except infants, where the predicted dose was 30 % under target. Other published models all made unacceptable predictions ([100 % of target) in at least one age group. These data further support the theory that allometric scaling combined with a maturation function provides a sound basis for describing clearance and predicting morphine doses in humans of all ages [7 •• ].
Thiopentone
Thiopentone is an old drug used in children of all ages. Although its use is disappearing, some still prefer this drug over propofol for neonatal intubation because it causes less peripheral vasodilation, and therefore less hypotension, in this age group [8 • ]. Reported pharmacokinetic parameter estimates have been derived from infusions administered for seizure control in neonates suffering hypoxic-ischaemic insults. While most clearance estimates are less than those in adults (200 mL/h/kg) [9] , interpretation is difficult because the hypoxic-ischaemic insult will also affect its clearance. Clearance is through oxidation (CYP2C19) to an inactive metabolite, thiopentone carboxylic acid. Immature hepatic enzymes in neonates decrease the oxidising capacity. CYP2C19 microsomal activity is approximately 30 % of mature values in the third trimester, but increases dramatically at birth [10] . A recent analysis of the maturation of thiopentone clearance using an allometric model with weight and a maturation model with PMA yielded results consistent with the maturation of CYP2C19. Clearance rapidly increases during the neonatal period from 33 mL/h/kg at 24 weeks postmenstrual age to 160 mL/h/kg at term [11 • ]. Neonates have less fat and muscle mass than adults and this is reflected in their reduced peripheral volume of distribution [11 • ]. A smaller clearance and peripheral volume of distribution means that plasma concentrations remain increased in neonates when compared with adults for a given dose. This is reflected in reduced dose requirements for neonates; the ED 50 of thiopentone is 3.4 mg/kg in neonates and 4.1 mg/kg in adolescents aged 12-16 years [12, 13] .
Etomidate
Etomidate is another old drug that continues to be used in children despite a lack of approval and a paucity of pharmacokinetic information. Pharmacokinetics have now been characterised in children (n = 49, 6 months-13 years) using an allometric model based on weight [14 • ]. The authors report an increased clearance and an increased central compartment volume of etomidate compared with adults. Consequently, younger children require a greater per-kilogram induction dose of etomidate compared with older children to achieve equivalent plasma concentrations [14 • ]. However, the use of etomidate has been plagued by concerns about adrenal suppression. These concerns have led to the development of a new compound, methoxycarbonyl-carboetomidate, which has a very rapid offset because of esterase hydrolysis, as well as virtually no adrenal suppression, while maintaining the potency of the parent compound [15] . This compound offers real promise and could offer an alternative to propofol for short term sedation.
Methadone
Intravenous methadone may be administered to pediatric patients undergoing posterior spinal fusion [16] and major abdominal surgery [17]. Methadone's long duration of action and N-Methyl-D-aspartate (NMDA) receptor antagonism are perceived as advantages for children who may experience prolonged pain. Methadone is cleared predominantly by the hepatic P450 cytochrome enzymes CYP2B6 and CYP3A4, and to a lesser extent by CYP2C19 [18] . These hepatic enzyme systems mature rapidly within the first few years of postnatal life [19] , and we might expect the PK after infancy to be similar to those described in young adults, if scaled using allometry [6] . However, the optimal dosing regimen for methadone remains uncertain because of sparse pharmacokinetic data in children and a paucity of analgesic effect data. It has been suggested that the analgesic EC 50 is 58 mcg/L in the opioid-naïve adult [20] , but comparable data in children are lacking, and whether these concentrations are achieved at the conclusion of spinal surgery is unknown. Recently, Sharma [21 • ] reported the PK of methadone in adolescents, however they presented a non-compartmental isomer analysis, making direct comparison to reported adult values awkward. Another compartmental analysis of the methadone racemate commonly used revealed that PK parameter estimates in adolescents are indeed similar to those reported in adults when scaled using allometry [22 • ]. Methadone undergoes rapid redistribution after bolus administration. This may result in plasma concentrations that provide inadequate analgesia postoperatively if the drug is given at the start of anesthesia. The authors suggested that an infusion (0.1-0.15 mg/kg/h) be used during spinal surgery to ensure adequate plasma concentrations for 24 h. Alternatively, subsequent dosing based upon pain severity (i.e., 0.03 mg/ kg for mild pain and 0.05 mg/kg for severe pain) every 4 h may provide sustained analgesia after bolus redistribution. Caution has been expressed against administering a large second bolus immediately after surgery because the concentration-response relationship for sedation and respiratory depression in opioid naïve children has not been elucidated [22 • ].
Nonsteroidal Anti-inflammatory Drugs (NSAIDs)
Conflicting reports plague the literature in terms of the relative analgesic efficacy of NSAIDs and acetaminophen, when administered individually. An early meta-analysis that compared single doses of acetaminophen, 7-15 mg/kg, with ibuprofen 4-10 mg/kg, reported similar analgesic effects in children [23] . However, a more recent meta-analysis concluded that ibuprofen was at least as effective, if not more than acetaminophen in both adults and children [24] . These conflicting results have been clarified by data from adults who were given ibuprofen after dental extraction. The maximum analgesic effect (1.54 of a scale 0-3) [25] was similar to that described for acetaminophen (5.3 of a scale 0-10) [26] . Importantly, the equilibration half-time (T 1/2 keo) of 28 min for ibuprofen was less than the 53 min reported for acetaminophen [26] and the slope of the concentrationresponse curve was steeper than that for acetaminophen. These data indicate that although these two NSAIDs may be equally efficacious, the onset of analgesia with ibuprofen is more rapid than that with acetaminophen.
NSAIDs reduce opioid consumption and the incidence of postoperative vomiting during in children [27 • ]. The effective dose of diclofenac has been estimated based on the assumption that attaining similar adult exposure to 50 mg in children should give similar effectiveness. This argument has been used to support a single dose of diclofenac 0.3 mg/kg for intravenous administration, 0.5 mg/ kg for suppositories, and 1 mg/kg for oral diclofenac in children aged 1-12 years [28
Interpretation of analgesia is also complicated by the effects of active metabolites. Diclofenac has a 4 0 -hydroxyl metabolite that contributes 30 % of the anti-inflammatory and antipyretic activity of the parent compound. The effect of parecoxib, a cyclooxygenase-2 selective inhibitor, is entirely through its active metabolite valdecoxib. These PK in children have been elucidated. The clearance of valdecoxib matures with a maturation half-time of 87 weeks PMA [29 • ], which is similar to that described for midazolam; a drug that is also cleared by primarily CYP3A4 with some contribution from CYP2C9 [30] . The authors used a similar approach to dosing as that used for diclofenac [28 •• ] . In order to achieve equivalent adult exposure to 40 mg IV, children (2-13 years) should be given 0.9 mg/kg IV if they weigh 10-14 kg, 0.8 mg/kg IV if 15-24 kg, 0.7 mg/kg IV if 24-39 kg and 0.6 mg/kg IV if 40-69 kg. These doses reflect the elimination clearance of parecoxib, which was scaled using allometry in children ages . This report is consistent with rat data that suggests ketamine is a respiratory stimulant that abolishes the coupling between loss-of-consciousness and upper airway dilator muscle dysfunction over a wide dose-range [33] . Adverse respiratory events are associated with large intravenous doses, administration to children younger than 2 years or aged 13 years or older, and the use of coadministered anticholinergics or benzodiazepines [34] .
'Ketofol' is a mixture of ketamine and propofol (1:1) that is finding a niche for procedural sedation in the emergency room. Stable hemodynamics, analgesia and good recovery are reported [35 • ]. This mixture is creeping into anesthetic practice, although the ideal mixture remains unknown. It is probable that the 'ideal mix' will depend on the duration of sedation required. The context sensitive half-times for propofol and ketamine increase with the duration of the infusion [36] . The limited number of prospective studies at this time precludes an assessment of safety and efficacy of this combination.
Acetaminophen
The release of an intravenous formulation of acetaminophen in the USA has increased interest in this drug. A population analysis [37] using allometry and a maturation model has confirmed earlier parameter estimates determined using propacetamol (an intravenous prodrug of acetaminophen) in children [38] . Intravenous acetaminophen in infants, children, and adolescents was well tolerated and achieved plasma concentrations similar to those achieved with labelled 15 mg/kg body weight doses by oral or rectal administration. In Europe, the PK of acetaminophen in neonates have been further explored. Weight was used to predict patient size and was the major covariate contributing 57.5 % of variance. Clearance expressed as mg/kg/h increases only slightly with PMA (0.138 L/kg/h at 28 weeks' PMA to 0.167 L/kg/h at 44 weeks' PMA). Using these estimates, a mean acetaminophen serum concentration of 11 mg/L is predicted in neonates of 32-44 weeks' PMA given a standard dose of intravenous acetaminophen of 10 mg/kg every 6 h [39 • ]. Safety data for this drug are limited in neonates and surveillance therefore remains essential. Tenfold dosing errors have occurred in paediatric practice and this error has been reported in neonates given IV acetaminophen [40] .
Future acetaminophen analyses may be simplified in part, through the use of 'blood spot' sampling. As little as 30 mcL of blood is spotted on to a Guthrie card, ensuring that the blood soaks through to the other side of the card and then allowed to dry at room temperature overnight in darkness. Blood spots are stored in sealed airtight plastic bags at 48°C in a secured fridge until chromatographic analysis [41, 42].
The Growing Obesity Issue

A Scaler for Dosing
Children presenting for adenotonsillectomy have a greater incidence of perioperative complications and are more likely to be admitted and/or remain in hospital for prolonged periods compared with their normal-weight peers [43, 44] . While simple measures such as neck circumference may warn practitioners of the increased incidence of postoperative respiratory complications [45] , a suitable index relating dose to body mass remains elusive.
Pharmacokinetic properties of some drugs are known to change in obesity [46] . Although body fat has minimal metabolic activity, fat mass contributes to overall body size and may have an indirect influence on both metabolic and renal clearance. On the other hand, the volume of distribution of a drug depends on its physicochemical properties [47] . The apparent volume of distribution of some drugs may be independent of fat mass (e.g., digoxin), whereas others are extensively determined by it (e.g., diazepam). To address the pharmacokinetic differences among drugs in obese patients, several size descriptors have been proposed for use in these patients including total body weight (TBW), lean body weight (LBW), ideal body weight (IBW), body mass index (BMI), fat free mass (FFM), normal fat mass (NFM).
One controversial issue is the selection of the optimal size descriptor to scale pharmacokinetic parameters when adjusting the dose of propofol for the obese patient [48, 49] . In normal-weight subjects, total body weight is a good size descriptor and a good approximation of lean body mass [48] . However, in obese patients, total body weight overestimates lean body mass because the increase in lean body mass only represents 20-40 % of total excess weight [46, [49] [50] [51] . As a result, the optimal size descriptor that provides the most accurate information about the relationship between propofol dose and its plasma concentrations remains unclear (Fig. 1) [49] .
Propofol
The effective dose of propofol for loss of lash reflex in obese pediatric patients (ED 95 2.0 mg/kg, 95 % CI 1.8-2.2 mg/kg) is less than that in their non-obese counterparts (3.2 mg/kg, 95 % CI 2.7-3.2 mg/kg). Obese children (BMI [95th percentile for age and gender) require a reduced weight-based dose of propofol for induction of anesthesia when compared with normal-weight children [54] . This has been attributed to the nonlinear relationship between weight and clearance. Although lean body weight has been proposed as the ideal measure for propofol [55, 56] , allometric scaling using total body weight with an exponent of 0.75 may be more appropriate [6, 57] . This same exponent has been advocated for the clearance of propofol in obese adults [58] and children [59] although a recent analysis suggested an exponent of 0.8 in obese children may be superior [60 • ]. We find it difficult to accept claims that the allometric coefficient differs from 0.75 based on an estimation from almost any realistic study design. The exponents 0.66, 0.75 and 0.85, for example, provide the same degree of accuracy or error in the [52] ) fails at weights greater than 120 kg. The use of body surface area (BSA) and allometry using an exponent of 0.75 are similar and diverge from lean body mass (LBM [53] ) over weights of 100 kg. The correct descriptor probably differs for each drug and will lie between the allometric and LBM curves. The relationship in children remains relatively unexplored prediction of clearance in children [6] . There is a real danger estimating the allometric exponent using a narrow range of children's weights. Investigators who focus only on obese subjects rather than a broad weight range that included normal-weight subjects, may not find a realistic allometric relationship [58] . Strange reports of negative exponents that imply clearance decreases with weight have been published [61] .
Another danger is attempting to use the 'one size descriptor fits all' approach to all drugs [62] . An allometric model using TBW may be appropriate for propofol, a drug with high fat solubility. However, this approach may be inappropriate for remifentanil, as lean body weight is a better size descriptor [63] . Hence, the size descriptor may differ for each drug. The use of normal fat mass with allometric scaling as a size descriptor may prove versatile [64] . That size descriptor uses the idea of fat fee mass (similar to LBW but excludes lipids in cell membranes, CNS and bone marrow) plus a 'bit more'. The 'bit more' will differ for each drug and the maximum 'bit more' added to fat free mass would equal TBW.
Alternative Delivery Routes
Exploration of alternative delivery routes for drugs in young children has centred on the nasal passages. Buccal and sublingual administration in children is unsatisfactory because they require prolonged exposure to the mucosal surface. Younger children find it difficult to comply with instructions to hold drugs in their mouths for the requisite retention time (particularly if the taste is unfavorable), and this results in more drug swallowed or expectorated than in adults. If the drug has a large first-pass effect then the reduced relative bioavailability decreases the plasma concentrations.
In contrast, the nasal route for opioid delivery is gaining popularity in children [65 •• ] . Nasal diamorphine, 0.1 mg/kg, is used in the UK for forearm fracture pain in the emergency room [66] [67] [68] [69] , but for the remainder of the world, fentanyl remains the stalwart. Nasal fentanyl (150 mcg/mL) 1.5 mcg/kg given to children (3-17 years) with fracture pain resulted in good analgesia. The pain score (VAS 0-100) decreased from 80 mm (IQR 60.0-95.5) to 49.5 mm (IQR 26.5-68.5) by 10 min and to 27.5 mm (IQR 18.5-56.5) by 20 min after administration [70, 71 • ]. Similar results have been reported for fentanyl (4 mcg/kg) administered through a standard nebulizer [72] . Studies in adults using a pectin-based gelling agent that modulates fentanyl absorption while limiting nasal drip or runoff hold promise and have proven useful in controlling breakthrough pain in adult cancer patients [73] . However, there remain few studies investigating the usefulness of intraoperative nasal fentanyl in children. It might be used in anesthesia where intravenous access is not always secured (e.g., myringotomy and ventilation tube placement). However, opioids are uncommonly required for such procedures and there remain concerns that intranasal drugs may pass through the posterior nasopharynx and irritate the vocal cords or through the cribriform plate and cause neurotoxicity [74 • ].
Advances in aerosol delivery devices have improved dosing accuracy. Administration of ketorolac 15 mg (weight \50 kg) or 30 mg (weight [50 kg) by the intranasal route resulted in a rapid increase in plasma concentration (time to peak (mean ± SD) concentration was 52 ± 6 min) and may be a useful therapeutic alternative to IV injection in adolescents because plasma concentrations attained with the device are likely to be analgesic. A target concentration of 0.37 mg/L in the effect compartment was achieved within 30 min and remained above that target for 10 h [75 • ]. It is somewhat concerning that these nasal doses are inconsistent with an adult meta-analysis that demonstrated that a single dose of systemic ketorolac is an effective adjunct in multimodal regimens to reduce postoperative pain and reduce postoperative nausea and vomiting. The 60-mg dose offered benefits, but there was a lack of current evidence that the 30-mg dose offered significant benefits on postoperative pain outcomes [76 • ]. The nasal dose may require revision.
Clonidine administered as a nasal aerosol (3-8 mcg/kg) did not achieve adequate preoperative sedation within 30 min of administration. Despite its sedative properties, postoperative sedation was not prolonged compared with placebo [77] . The oral bioavailability of clonidine is also poor (F = 0.55) in children 3-10 years. Consequently, larger oral doses (per kg) are required when this formulation is used to achieve concentrations similar to those reported in adults [78] .
Similarly, oral ketamine needs to be given in doses of up to 10 mg/kg to achieve therapeutic effects in children 1-8 years with burns [79 • ]. This contrasts with a dose of 4-6 mg/kg oral ketamine for premedication in healthy children. These differing dose requirements may be explained by differences in the absorption characteristics of children with burns. Not only was bioavailability reduced (F = 0.45) but absorption was also slow; absorption halftime was 59 min and inter-subject variability was large in this cohort. Dose simulation in a burned child (3.5 years, 15 kg) suggested a dosing regimen of oral ketamine, 10 mg/kg, followed by intravenous ketamine, 1 mg/kg at 45 min for a brief surgical dressing change [79 • ].
Drug Interactions
Acetaminophen-Ibuprofen
Acetaminophen and NSAIDs can be safely combined without increasing their associated adverse-effect profiles.
As a result, combination therapy has become very popular. A review of randomized controlled studies identified six studies that compared combined acetaminophen and ibuprofen therapy for postoperative pain [80] . Of these, three were conducted in pediatric populations: oral premedication with the combination was superior to acetaminophen alone for pain after tonsillectomy in children and after tooth extraction, while rectal administration of the combination did not differ from acetaminophen alone for pain after adenoidectomy. However, in the latter study, the need for rescue analgesia was reduced in the combination group at home.
These disparate results may be explained as follows. Dose-response curves for the combination therapy in adults suffering dental pain have been published [81] . Analysis of those data using a response surface area allowed dose interpretation in children [82 • ]. Simulation for a 20-kg child showed that the addition of acetaminophen to ibuprofen in doses less than 5 mg/kg reduced the pain response, whereas acetaminophen added to ibuprofen in doses greater than 5 mg/kg had minimal effect in the immediate postoperative period. A more sustained analgesic effect was noted at 4-8 h after combination therapy. Combination therapy achieves effective analgesia with a reduced daily dose of acetaminophen (e.g., 60 mg/kg/day), and therefore reduced concern of hepatotoxicity. Unfortunately, combination therapy does not provide prolonged analgesia sufficient to maintain adequate analgesia overnight [83] .
Ketamine-Phenobarbital
Drug interactions may also be the consequence of prolonged therapy. Phenobarbital, used for seizure control, induces CYP3A4 [84] , an enzyme responsible for ketamine clearance. Ketamine, which is metabolized by CYP3A4, has a reduced sedative effect in children who are receiving long-term phenobarbital therapy [85, 86] .
Combination Therapy for Tracheal Intubation Without Neuromuscular Blocking Drugs
Although succinylcholine is considered the golden standard for optimizing intubating conditions, tracheal intubation without prior administration of muscle relaxants is common. A systematic review identified several drug combinations for induction of anesthesia with sevoflurane or propofol in children aged 1-9 years. One combination used sevoflurane and propofol (3 mg/kg) without premedication, and spontaneous breathing showed that propofol may be the adjuvant of choice for a rapid sevoflurane induction. The only adjuvant identified during a propofol induction was IV remifentanil (4 mcg/kg) [87 • ].
Pharmacodynamic Considerations
Anesthesia Monitoring
Bispectral monitoring (BIS) has become acceptable in adults as a measure of anesthesia depth. However, there remains a need for specific neonate-derived algorithms if EEG-derived anesthesia depth monitors are to be used in neonates. Problems with BIS monitoring in young children include a paradoxical increase when the sevoflurane concentrations exceed 3 %, differences between the right and left side of the brain, discrepant BIS values among inhalational agents at equivalent MAC values, and BIS values in children that exceeded those in adults at equivalent MAC values [88] . An explanation for the last finding is that brain structure sensitivities differ with brain maturation [89] . Data also suggest that the spectral entropy for deep sedation and surgical anesthesia in children 3-6 years exceed those in children 6-16 years during propofol-remifentanyl infusion [90] . However, these results are also consistent with dose scaling based on allometry. Because clearance is increased in children, younger children have lower drug concentrations when the same infusion (per kilogram) is administered in all ages, as was the case in that study.
Pharmacodynamic Covariates
Considerable strides have been made identifying pharmacodynamic covariates. Bradycardia during anesthetic induction with sevoflurane was common in children with Down syndrome [91] . Critical illness is a major determinant for the clearance of midazolam [92 • ]. Opioid administration was reduced in otherwise healthy children with altitude-induced chronic hypoxia when compared with non-hypoxic children undergoing similar operations under similar anesthetic regimens [93] . Opioid dose also appears to vary geographically; that is, children in Central and South America receive less opioid intraoperatively than do children in Africa and India, under standardized anesthesia for cleft surgeries [94 • ]. Ethnicity may contribute to this observation. There were differences in the occurrence of adverse effects after morphine administration between Latino and non-Latino Caucasian children. Neither differences in morphine or metabolite concentrations, nor the genetic polymorphisms examined, explained these findings
The management of postoperative pain can only improve with greater understanding of its severity and duration. Children experience significant pain and severe functional limitation up to 7 days after tonsillectomy or orchidopexy; effects that may persist into the second postoperative week [96] . Substantial pain persists on day 2 even after laparoscopic appendicectomy [97] . Children with intellectual disability (e.g., Trisomy 21) suffer postoperative pain to a similar effect as unaffected children, leading many to advocate similar perioperative analgesia care for the two groups [98, 99 • 
''Jet lag'' After Anesthesia Children often experience sleep disturbance after anesthesia. Part of this effect may be attributed to disruption of the internal circadian clock. The honey bee has a circadian clock that is similar to that found in humans. After a 6 h anaesthetic, bees showed a delay in the start of foraging and whole-hive locomotor-activity rhythms that were delayed by an average of 4.3 h. Messenger RNA of circadian clock genes was altered by anesthetic exposure, suggesting that general anesthesia alters the circadian clock in a manner consistent with jet lag [100 •• ].
Conclusion
Our knowledge of pediatric pharmacology as it pertains to the anesthesiologist continues to expand. However, translation of this knowledge into practical anesthesia has been haphazard and incomplete. By investigating the complex PK of a drug, interactions between drugs, and the pharmacodynamic effects of these findings in different subpopulations of infants and children, we can identify the key covariates that will enable clinicians to prescribe effective doses of drugs while limiting the adverse effects in the individual child. 
